Patents by Inventor Tacey X. Viegas
Tacey X. Viegas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230009076Abstract: The present disclosure provides for polyoxazoline (POZ) conjugates wherein the conformation of the POZ conjugate and the release rate of an agent from the POZ conjugate can be controlled by selecting one or more characteristics of the POZ polymer. Methods of controlling the conformation of a POZ conjugate and the release rate of an agent prior are provided as well as methods of treatment using such POZ conjugates and methods. Pharmaceutical compositions comprising a POZ conjugate are also provided.Type: ApplicationFiled: June 28, 2020Publication date: January 12, 2023Applicant: SERINA THERAPEUTICS, INC.Inventors: J Milton HARRIS, Michael D BENTLEY, Tacey X VIEGAS, Randall W MOREADITH, Zhihao FANG, Kunsang YOON, Rebecca WEIMER
-
Publication number: 20220079936Abstract: Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.Type: ApplicationFiled: November 24, 2021Publication date: March 17, 2022Inventors: Xuan Zhao, Michael D. Bentley, Zhongxu Ren, Tacey X. Viegas
-
Publication number: 20210393513Abstract: Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchoalveolar lavage followed by assaying residual lung material.Type: ApplicationFiled: August 23, 2021Publication date: December 23, 2021Inventors: C. Simone Jude-Fishburn, David Lechuga-Ballesteros, Tacey X. Viegas, Mei-Chang Kuo, Hema Gursahani, Chester Leach, Yuan Song
-
Patent number: 11129794Abstract: Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchioalveolar lavage followed by assaying residual lung material.Type: GrantFiled: June 27, 2018Date of Patent: September 28, 2021Assignee: Nektar TherapeuticsInventors: C. Simone Jude-Fishburn, David Lechuga-Ballesteros, Tacey X. Viegas, Mei-Chang Kuo, Hema Gursahani, Chester Leach, Yuan Song
-
Publication number: 20200016149Abstract: Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.Type: ApplicationFiled: September 25, 2019Publication date: January 16, 2020Inventors: Xuan Zhao, Michael D. Bentley, Zhongxu Ren, Tacey X. Viegas
-
Patent number: 10463659Abstract: Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.Type: GrantFiled: October 3, 2017Date of Patent: November 5, 2019Assignee: Nektar TherapeuticsInventors: Xuan Zhao, Michael D. Bentley, Zhongxu Ren, Tacey X. Viegas
-
Publication number: 20190099363Abstract: Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchioalveolar lavage followed by assaying residual lung material.Type: ApplicationFiled: June 27, 2018Publication date: April 4, 2019Inventors: C. Simone Fishburn, David Lechuga-Ballesteros, Tacey X. Viegas, Mei-Chang Kuo, Hema Gursahani, Chester Leach, Yuan Song
-
Publication number: 20180021444Abstract: Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.Type: ApplicationFiled: October 3, 2017Publication date: January 25, 2018Inventors: Xuan Zhao, Michael D. Bentley, Zhongxu Ren, Tacey X. Viegas
-
Patent number: 9808533Abstract: Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.Type: GrantFiled: May 2, 2016Date of Patent: November 7, 2017Assignee: Nektar TherapeuticsInventors: Xuan Zhao, Michael David Bentley, Zhongxu Ren, Tacey X. Viegas
-
Publication number: 20170095565Abstract: Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchoalveolar lavage followed by assaying residual lung material.Type: ApplicationFiled: June 9, 2016Publication date: April 6, 2017Inventors: Michael D. Bentley, Tacey X. Viegas, Richard R. Goodin, Lin Cheng, Xuan Zhao
-
Publication number: 20170056514Abstract: Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.Type: ApplicationFiled: May 2, 2016Publication date: March 2, 2017Inventors: Xuan Zhao, Michael David Bentley, Zhongxu Ren, Tacey X. Viegas
-
Patent number: 9388104Abstract: Provided are methods of preparing a monodisperse oligo (ethylene glycol) reagent composition.Type: GrantFiled: April 8, 2014Date of Patent: July 12, 2016Assignee: Nektar TherapeuticsInventors: Michael D. Bentley, Tacey X. Viegas, Richard R. Goodin, Lin Cheng, Xuan Zhao
-
Patent number: 9333200Abstract: Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.Type: GrantFiled: July 3, 2014Date of Patent: May 10, 2016Assignee: Nektar TherapeuticsInventors: Xuan Zhao, Michael David Bentley, Zhongxu Ren, Tacey X. Viegas
-
Patent number: 9107956Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the small molecule drug not attached to the water-soluble oligomer.Type: GrantFiled: October 16, 2013Date of Patent: August 18, 2015Assignee: NEKTAR THERAPEUTICSInventors: Jennifer Riggs-Sauthier, Lin Cheng, Tacey X. Viegas, Xuyuan Gu, Franco J. Duarte, Wen Zhang
-
Publication number: 20150197470Abstract: Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchoalveolar lavage followed by assaying residual lung material.Type: ApplicationFiled: April 8, 2014Publication date: July 16, 2015Applicant: Nektar TherapeuticsInventors: Michael D. BENTLEY, Tacey X. Viegas, Richard R. Goodin, Lin Cheng, Xuan Zhao
-
Publication number: 20150174264Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the small molecule drug not attached to the water-soluble oligomer.Type: ApplicationFiled: March 6, 2015Publication date: June 25, 2015Applicant: Nektar TherapeuticsInventors: Jennifer Riggs-Sauthier, Wen Zhang, Tacey X. Viegas, Michael D. Bentley
-
Publication number: 20140371258Abstract: Provided herein are water-soluble polymer conjugates of topotecan, along with compositions comprising the conjugates and related methods of making and using the same.Type: ApplicationFiled: December 16, 2011Publication date: December 18, 2014Applicant: Nektar TherapeuticsInventors: Xuyuan Gu, Jennifer Riggs-Sauthier, Michael D. Bentley, Tacey X. Viegas
-
Publication number: 20140323514Abstract: Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.Type: ApplicationFiled: July 3, 2014Publication date: October 30, 2014Inventors: Xuan Zhao, Michael David Bentley, Zhongxu Ren, Tacey X. Viegas
-
Publication number: 20140303403Abstract: Methods of modifying the rate of systemic absorption of a drug administered to a subject by a pulmonary route, the method comprising covalently conjugating a hydrophilic polymer to a drug, wherein the drug has a half-life of elimination from the lung of less than about 180 minutes, to form a drug-polymer conjugate, wherein the drug-polymer conjugate has a net hydrophilic character and a weight average molecular weight of from about 50 to about 20,000 Daltons, and wherein the half-life of elimination from the lung of the drug-polymer conjugate is at least about 1.5-fold greater than the half-life of elimination from the lung of the drug, wherein the half-life of elimination from the lung is measured by bronchoalveolar lavage followed by assaying residual lung material.Type: ApplicationFiled: April 8, 2014Publication date: October 9, 2014Applicant: Nektar TherapeuticsInventors: Michael D. BENTLEY, Tacey X. Viegas, Richard R. Goodin, Lin Cheng, Xuan Zhao
-
Patent number: 8771662Abstract: Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.Type: GrantFiled: February 12, 2013Date of Patent: July 8, 2014Assignee: Nektar TherapeuticsInventors: Xuan Zhao, Michael David Bentley, Zhongxu Ren, Tacey X. Viegas